A recent Phase II clinical trial by Bachert et al. showed that dupilumab, a fully human monoclonal antibody targeting the α subunit shared by IL-4 and IL-13 receptors, significantly improved clinical, endoscopic, radiological, and pharmacodynamic outcomes in patients with nasal polyposis after 16 weeks [76]. Here, IL4 is linked to Nasal polyposis.